[HTML][HTML] Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - Saudi Pharmaceutical …, 2020 - Elsevier
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways.
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - … Journal: SPJ: the …, 2020 - europepmc.org
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
[HTML][HTML] Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - Saudi Pharmaceutical …, 2020 - ncbi.nlm.nih.gov
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
AF AlAsmari, N Ali, F AlAsmari… - … journal: SPJ: the …, 2020 - pubmed.ncbi.nlm.nih.gov
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
[PDF][PDF] Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-jB signaling pathways
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - researchgate.net
abstract Gefitinib is an effective treatment for patients with locally advanced non-small cell
lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use …
lung cancer. However, it is associated with cardiotoxicity that can limit its clinical use …
Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
AF AlAsmari, N Ali, F AlAsmari… - Saudi Pharmaceutical …, 2020 - ksascholar.dri.sa
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways.
AF AlAsmari, N Ali, F AlAsmari, WA AlAnazi… - … Journal: SPJ: the …, 2020 - europepmc.org
Gefitinib is an effective treatment for patients with locally advanced non-small cell lung
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …
cancer. However, it is associated with cardiotoxicity that can limit its clinical use. Liraglutide …